The tricuspid valve: Current perspective and evolving management of tricuspid regurgitation

Jason H Rogers, Steven F. Bolling

Research output: Contribution to journalArticlepeer-review

283 Scopus citations


Cardiovascular specialists have entered an era of renewed interest and enthusiasm surrounding the diagnosis and treatment of valvular heart disease, driven in part by emerging percutaneous therapies for the treatment of aortic, pulmonic, and mitral valve disease. Despite this wave of investigation, little or no attention has been given to the treatment of tricuspid valve disease. Tricuspid regurgitation (TR) occurs mainly from tricuspid annular dilation, which can result from left-sided heart failure from myocardial or valvular causes, right ventricular volume and pressure overload, or dilation of cardiac chambers. If untreated at the time of surgical mitral valve repair, significant residual TR negatively impacts perioperative outcomes, functional class, and survival. TR does not reliably resolve after successful mitral valve surgery. If present at the time of mitral valve surgery, TR can usually be effectively addressed with ring annuloplasty. Because reoperations for recurrent TR carry high mortality rates, few patients are offered reoperation for redo tricuspid repair or replacement. As transcatheter therapies for mitral regurgitation arise, parallel percutaneous approaches for TR may be necessary. In this article, we review the anatomy, pathophysiology, and value of mechanical correction of TR, including potential transcatheter therapies for TR.

Original languageEnglish (US)
Pages (from-to)2718-2725
Number of pages8
Issue number20
StatePublished - May 26 2009


  • Catheters
  • Surgery
  • Valve, tricuspid
  • Valves

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'The tricuspid valve: Current perspective and evolving management of tricuspid regurgitation'. Together they form a unique fingerprint.

Cite this